Azelastine and olopatadine in the treatment of allergic rhinitis (Q37635840)

21 August 2017

1 reference

title

Azelastine and olopatadine in the treatment of allergic rhinitis (English)

1 reference

21 August 2017

1 reference

Michael A Kaliner

1

1 reference

21 August 2017

publication date

1 November 2009

1 reference

Annals of Allergy, Asthma & Immunology

21 August 2017

published in

1 reference

21 August 2017

volume

103

1 reference

21 August 2017

issue

5

1 reference

21 August 2017

page(s)

373-380

1 reference

The diagnosis and management of rhinitis: an updated practice parameter

21 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Allergic rhinitis and its impact on asthma

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

1 reference

7 January 2021

Histamine H4 receptor mediates chemotaxis and calcium mobilization of mast cells

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Direct expenditures for the treatment of allergic rhinoconjunctivitis in 1996, including the contributions of related airway illnesses

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Azelastine hydrochloride: a review of pharmacology, pharmacokinetics, clinical efficacy and tolerability

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

The interaction of azelastine with human lung histamine H1, beta, and muscarinic receptor-binding sites

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

A dose-ranging study of the efficacy and safety of azelastine nasal spray in the treatment of seasonal allergic rhinitis with an acute model

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Azelastine nasal spray and desloratadine tablets in pollen-induced seasonal allergic rhinitis: a pharmacodynamic study of onset of action and efficacy

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Onset of action of azelastine nasal spray compared with mometasone nasal spray and placebo in subjects with seasonal allergic rhinitis evaluated in an environmental exposure chamber

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

A double-blind, controlled trial to assess the safety and efficacy of azelastine nasal spray in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Safety and efficacy of azelastine nasal spray (Astelin NS) for seasonal allergic rhinitis: a 4-week comparative multicenter trial

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Efficacy and safety of azelastine nasal spray at a dose of 1 spray per nostril twice daily

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Pharmacokinetic characteristics and safety and tolerability of a reformulated azelastine hydrochloride nasal spray in patients with chronic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Efficacy of azelastine nasal spray in the treatment of vasomotor (perennial nonallergic) rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

The in vitro and in vivo ocular pharmacology of olopatadine (AL-4943A), an effective anti-allergic/antihistaminic agent

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Onset and duration of action of nasal sprays in seasonal allergic rhinitis patients: olopatadine hydrochloride versus mometasone furoate monohydrate

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis to mountain cedar

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Comprehensive report of the efficacy, safety, quality of life, and work impact of Olopatadine 0.6% and Olopatadine 0.4% treatment in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Improved quality of life among seasonal allergic rhinitis patients treated with olopatadine HCl nasal spray 0.4% and olopatadine HCl nasal spray 0.6% compared with vehicle placebo

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Effects of olopatadine hydrochloride nasal spray 0.6% in the treatment of seasonal allergic rhinitis: a phase III, multicenter, randomized, double-blind, active- and placebo-controlled study in adolescents and adults.

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Efficacy of azelastine nasal spray in patients with an unsatisfactory response to loratadine

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Efficacy of azelastine nasal spray in seasonal allergic rhinitis patients who remain symptomatic after treatment with fexofenadine

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Effectiveness of azelastine nasal spray compared with oral cetirizine in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Impact of azelastine nasal spray on symptoms and quality of life compared with cetirizine oral tablets in patients with seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Meta-analysis of azelastine nasal spray for the treatment of allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Intranasal corticosteroids versus topical H1 receptor antagonists for the treatment of allergic rhinitis: a systematic review with meta-analysis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Comparison of olopatadine 0.6% nasal spray versus fluticasone propionate 50 microg in the treatment of seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Comparison of beclomethasone dipropionate aqueous nasal spray, astemizole, and the combination in the prophylactic treatment of ragweed pollen-induced rhinoconjunctivitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Effects of levocetirizine as add-on therapy to fluticasone in seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

Randomized placebo-controlled trial comparing fluticasone aqueous nasal spray in mono-therapy, fluticasone plus cetirizine, fluticasone plus montelukast and cetirizine plus montelukast for seasonal allergic rhinitis

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

A novel and effective approach to treating rhinitis with nasal antihistamines

1 reference

https://api.crossref.org/works/10.1016/S1081-1206(10)60355-9

7 January 2021

10.1016/S1081-1206(10)60355-9

Identifiers

DOI

1 reference

21 August 2017

1 reference